Taken all together, therapeutic oligonucleotides are a potential alternative to antibodies and small molecule inhibitors to silence the expression of the ERBB2 gene and could overcome some of the inconvenients of the standard treatments for HER-2 positive breast cancers. The gene discussed is ERBB2; the disease is breast carcinoma.